Citations

Clear

2429 citation(s) found for "Shah, SS".

Tafamidis treatment significantly reduces the risk of recurrent cardiovascular-related hospitalisation in patients with early stage transthyretin amyloid cardiomyopathy
Damy, T, Witteles, R, Shah, S, Marino, Valentina , Wang, R, Grogan, M, Damy, Thibaud , Witteles, R, Cappelli, Francesco , Marino, V, Wang, R

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.1221 Get It

Abstract Background The clinical efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) was demonstrated during the phase 3, multinational, randomised, placebo-controlled Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT).(1) In ATTR-ACT, the risk of any cardiovascular (CV)-related hospitalisation was significantly reduced among patients who received tafamidis meglumine 80 mg (the approved dose) vs placebo (relative risk ratio 0.70 [95% CI 0.57, 0.85]; P=0.0005).(2) The benefit of tafamidis treatment was largest among patients with New York Heart Association (NYHA) class I/II vs III symptoms at baseline.(1,3,4) Purpose ATTR-CM is a progressive disease with a natural history that typically includes an increasing frequency of CV-related hospitalisation as the condition worsens. This post hoc analysis adds to current knowledge by evaluating the risk of recurrent (≥1) CV-related hospitalisation by baseline NYHA class in ATTR-ACT patients taking the approved dose of tafamidis or placebo. Methods Patients aged 18 to 90 years with biopsy-confirmed wild-type or variant ATTR-CM and NYHA class I-III symptoms took part in ATTR-ACT between 2013 and 2018. During the trial, the cause of hospitalisation was adjudicated by an independent committee. The hazard ratio (HR) for first CV-related hospitalisation was calculated using a Cox proportional hazards model. The HR for recurrent CV-related hospitalisation was calculated using the Liu-Wei-Yang-Ying (LWYY; also known as the modified Anderson-Gill) model. Models compared tafamidis meglumine 80 mg vs placebo and adjusted for transthyretin genotype (wild-type or variant). In the overall population, the LWYY model was also adjusted for baseline NYHA class. Results The frequency of adjudicated CV-related hospitalisations during ATTR-ACT by NYHA class are shown in the Figure. Across patients who were NYHA class I-III at baseline, the risk of recurrent CV-related hospitalisation was 37% lower in those who received tafamidis vs placebo treatment (HR 0.627 [95% CI 0.463, 0.848]; P=0.0025; Table). Among those who were NYHA class I/II at baseline, a lower proportion of tafamidis- vs placebo-treated patients (44% vs 61%) had ≥1 CV-related hospitalisation. The risks of first and recurrent CV-related hospitalisation were 40% (HR 0.601 [95% CI 0.420, 0.861]; P=0.0055) and 55% (HR 0.449 [95% CI 0.305, 0.661]; P<0.0001) lower with tafamidis vs placebo treatment. Consistent with the survivor bias previously observed in ATTR-ACT,(1-4) the risk of recurrent CV-related hospitalisation was statistically similar in tafamidis- and placebo-treated patients who were NYHA class III at baseline (HR 1.113 [95% CI 0.688, 1.799]; P=0.6624). Conclusions Building on previous findings, this analysis found the risk of recurrent CV-related hospitalisation to be reduced by tafamidis meglumine 80 mg treatment in patients with early stage ATTR-CM.
Addressing recurrent pericarditis: assessing patient and professional education needs
Klein, A, Wang, T, Weber, B N, Abbate, A, Kohnstamm, S, Luis, S A, Cremer, P, Al-Kazaz, M, Shah, D, Wang, L, Sabet, Amin , Tadwalkar, R, Participants, A H A Addressing Recurrent Pericarditis Initiative, Staff, A H A Addressing Recurrent Pericarditis, Cremer, Paul , Cremer, Paul C , Klein, Allan L. , Wang, T, Weber, Brittany , Abbate, Antonio , Salik, Jonathan R. , Kohnstamm, Sarah, Luis, S A, Al‐Kazaz, Mohamed

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.4512 Get It

Abstract Background Nearly 40,000 people in the U.S. experience recurrent pericarditis with up to 90% of cases having no identifiable cause, often making the journey to diagnosis arduous. Understanding the challenges that patients and health care professionals (HCP) face will help address gaps and barriers in patient diagnosis and care. In addition, the lack of U.S. based guidelines for recurrent pericarditis clinical care, coupled with the time lapse from the last published European guideline, has created an opportunity to discover workflow solutions for U.S. based healthcare professionals. Purpose The American Heart Association’s (AHA) Addressing Recurrent Pericarditis Initiative is a three-year effort utilizing a quality improvement approach to address gaps/barriers in patient care, educate HCPs, and develop patient education resources to improve diagnosis, treatment, and quality of life. To accomplish this, the lived experiences and challenges patients face on their journey to diagnosis was integrated into the qualitative research process. Methods To assess quality improvement opportunities, the AHA engaged HCPs with recurrent pericarditis experience from 15 diverse health systems to participate in a learning collaborative strategy for quality improvement and implementation to share successful strategies, provide input on professional education topics, and participate in process mapping. Data collection strategies include 1:1 consultations, quarterly learning collaborative calls, surveys and questionnaire completion. To assess patient education needs, the AHA Market Research Team held 1-hour video interviews with ten diverse patients. Results AHA-led HCP interviews produced process maps of clinical workflows and identified opportunities for standardization to improve clinical workflow and patient outcomes (Figure 1). From these data collection methods, preliminary results include care coordination across clinical settings, exploring treatment options, standardization of follow-up cadence, and provider awareness of misdiagnoses/underdiagnosis rates. The patient interviews revealed that there is a lack of symptom recognition, persistent rate of misdiagnosis, delay in accurate diagnosis and treatment, and discrepancies in diagnosis and treatment for various demographics including female and younger adult patients (Figure 2). Conclusion(s) In Year 2 of this three-year initiative, we will continue to refine identified areas of opportunities to improve patient outcomes by creating and disseminating educational materials and launch awareness campaigns, while also producing a national education series for HCPs that provide guidance for system-level quality improvement to emphasize consistency in care and reductions in health inequities. Key findings from this study highlight the care coordination involved in the treatment of patients with recurrent pericarditis and the need to provide multidiscipline educational approaches to achieve this goal.Figure. 1 Summary of care pathway Figure. 2 Summary of patient interviews
Not So Benign Telomere Biology Disorders: Not So Benign, Not So Rare, and Not Limited to Pediatrics
Mangaonkar, Abhishek A. , Shah, Surbhi, Patnaik, Mrinal M.

Mayo Clinic

The Hematologist | February 2, 2026 | Volume: 23 | Issue: 1 | Pages: No page available

10.1182/hem.v23.1.202612 Get It

Optimizing tuberculosis post-exposure follow-up among healthcare personnel using a risk-based approach
Samreen, Ayesha, Swift, Melanie D. , Breeher, Laura E. , Apenhorst, Debra, Rasmusson, Jenna, Loeffler, April, Anderson, J. Simon, Shah, Aditya , Samreen, Ayesha , Samreen, Ayesha , Apenhorst, Debra K, Rasmusson, Jenna M., Loeffler, April R, Anderson, Jennifer A, Shah, Aditya S , Swift, Melanie D , Breeher, Laura , Anderson, Jennifer A.

Mayo Clinic

Infection Control & Hospital Epidemiology | February 2, 2026 | Volume: 47 | Issue: 5 | Pages: 530-532

10.1017/ice.2026.10403 | PMID 41623146 Get It

Abstract Healthcare personnel (HCP) are at risk for occupational exposure to tuberculosis. Current guidelines for managing exposed HCP are broad and resource intensive. Based on review of our internal data, we propose a risk-based stratification approach to streamline exposure follow-up testing and optimize resource utilization.
Dysplasia detection using high-definition scopes with dye vs virtual chromoendoscopy in IBD: A meta-analysis of randomized clinical trials
Mohamed, Mouhand F. H., Chu, Jacqueline J. , Beran, Azizullah, Ahmed, Khalid , Shah, Samir , Nayfeh, Tarek

Mayo Clinic

Inflammatory Bowel Diseases | January 23, 2026 | Volume: 32 | Issue: 7 | Pages: 1410-1414

10.1093/ibd/izag019 | PMID 41701117 Get It

Lay Summary This meta-analysis of 8 randomized controlled trials compares the effectiveness of using high-definition scopes with virtual chromoendoscopy vs dye chromoendoscopy for detecting dysplasia in inflammatory bowel disease patients. Overall, the odds of dysplasia detection were not significantly different between dye chromoendoscopy and virtual chromoendoscopy.
Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study
Alsina, Melissa , Shah, Nina, Jagannath, Sundar, Kaufman, Jonathan L., Siegel, David, Munshi, Nikhil C., Rosenblatt, Jacalyn , Lin, Y, Jakubowiak, Andrzej , Li, Aojun, Mao, Pingping, Fincker, Maeva, Yeri, Ashish , Campbell, Timothy , Finney, Olivia , Truppel-Hartmann, Anna, Petrocca, Fabio , NS, Raje, Jagannath, Sundar , Kaufman, Jonathan L. , Lin, Yi , Siegel, David S. , Shah, Nina , Jagannath, Sundar , Kaufman, Jonathan L , Siegel, David , Munshi, Nikhil C , Lin, Yi , Jakubowiak, Andrzej , Derman, Benjamin A , Li, Aojun , Mao, Pingping , Fincker, Maeva , Yeri, Ashish , Martin, Nathan , Campbell, Timothy , Finney, Olivia , Truppel-Hartmann, Anna , Petrocca, Fabio , Berdeja, Jesús G , Raje, Noopur S , Munshi, Nikhil C. , Derman, Benjamin A. , Martin, Nathan , Berdeja, Jesús G.

Mayo Clinic

Cancer Immunology Research | January 21, 2026 | Volume: 14 | Issue: 4 | Pages: 528-542

10.1158/2326-6066.cir-24-0527 | PMID 41562447 Get It

Abstract Chimeric antigen receptor (CAR) T-cell therapy enriched for a memory-like phenotype may persist and function longer than a nonenriched product, thereby improving duration of response (DOR). We conducted a phase I study with bb21217 (NCT03274219), an anti–B-cell maturation antigen CAR T-cell therapy manufactured in the presence of the phosphoinositide 3-kinase inhibitor bb007 to enrich for T cells with a memory-like phenotype, in patients with relapsed/refractory multiple myeloma (N = 72). No new safety concerns were raised with bb21217 therapy (three cases each of grade ≥3 cytokine release syndrome and grade ≥3 neurotoxicity were observed). The objective response rate was 69.4% and the median DOR was 23.8 (95% confidence interval, 16.8–34.8) months. Analysis of the drug product established an association between early memory phenotype and robust expansion and depth of response. Examination of baseline characteristics indicated that tumor burden and prior therapies influenced DOR. The data indicate that generation of CAR T cells early in a disease course when tumor burden is lower and source material exhibits a more naïve phenotype may maximize the clinical benefit potential of the drug product.
Patterns of Antiphospholipid Antibody Testing and Positivity in a Real-World Laboratory over Two Decades: The Role of IgM
Jiménez, María Camila , Duarte-García, Ali, Pruthi, Rajiv K. , Alyamany, Ruah , Shah, Surbhi , Wysokinska, Ewa , Lizarazo Jimenez, Maria, McBane, Robert D. , Houghton, Damon E. , Duarte‐García, Alí , Casanegra, Ana I.

Mayo Clinic

Seminars in Thrombosis and Hemostasis | January 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2778-9641 | PMID 41558525 Get It

Impact of Kidney Replacement Therapy During Extracorporeal Membrane Oxygenation Support in Terms of Mortality: A Systematic Review and Meta‐Analysis
Sah, Ranjit , Paudel, Amita, Shah, Sangam , Bhattarai, Madhur , Bhandari, Sujata , Adhikari, Bishwa Raj, Sah, Sanjit, Mehta, R., Guru, Pramod, Chaudhary, Sanjay, Sah, Ranjit , Mehta, Rachana , Shah, Sangam , Sah, Sanjit Kumar , Mehta, Rachana , Bhattacharyya, Anirban , Franco, Pablo Moreno , Guru, Pramod , Chaudhary, Sanjay

Mayo Clinic

Health Science Reports | January 20, 2026 | Volume: 9 | Issue: 1 | Pages: No page available

10.1002/hsr2.71742 | PMID 41568124 Get It

ABSTRACT Introduction Extracorporeal membrane oxygenation (ECMO) is a life‐saving intervention for refractory cardiopulmonary failure. Despite advancements reducing complications, ECMO remains associated with acute kidney injury (AKI), often requiring kidney replacement therapy (KRT). Studies report up to 45% of ECMO patients needing KRT, significantly increasing mortality. A prior meta‐analysis suggested a declining mortality trend in recent years. Methodology Following PRISMA guidelines, PubMed, MEDLINE, EMBASE, and Cochrane Library were searched (2000–2024) for randomized and observational studies on adult ECMO patients requiring KRT. Data extraction covered study characteristics, patient demographics, ECMO type, KRT timing, and clinical outcomes. Quality was assessed using the Newcastle–Ottawa Scale. Statistical analyses were performed using RevMan 5.4.1 under a random‐effects model, with mortality as the primary outcome. Result A total of 24 studies (6347 patients) met the inclusion criteria, including 23 observational studies and one RCT. The mean age of ECMO + KRT patients was 51 years in observational studies and 61.2 years in the RCT, with cardiogenic shock as the most common ECMO indication. Meta‐analysis showed a significantly higher mortality in ECMO + KRT patients (RR: 1.86, 95% CI: 1.63–2.12, p < 0.001), with infections and bleeding as key contributors. Subgroup analysis revealed no significant survival difference based on KRT timing, while Veno‐arterial extracorporeal membrane oxygenation (VA‐ECMO) was associated with worse outcomes than Veno‐venous extracorporeal membrane oxygenation (VV‐ECMO). The RCT reported 61.9% mortality at 30 days in ECMO + KRT patients. Conclusion KRT during ECMO is associated with increased mortality, likely due to the severity of illness and complications like infections and bleeding. The optimal timing of KRT initiation remains unclear, and no significant survival benefit was found for early KRT. Further large‐scale RCTs are needed to optimize management strategies.
Structural Augmentation in Rotator Cuff Repair Decreases the Risk of Retear: A Systematic Review and Meta-analysis
Dagher, Danielle , Shah, Darshil, Kruse, Colin , Khalik, Hassaan Abdel , Saleh, Usama, Hachem, Abdul-ilah, Tokish, John, Bedi, Asheesh , Khan, Moin , Abdel Khalik, Hassaan , Shah, Darshil , Hachem, Abdul-ilah

Mayo Clinic

The American Journal of Sports Medicine | January 19, 2026 | Volume: 54 | Issue: 6 | Pages: 1525-1536

10.1177/03635465251400356 | PMID 41549444 Get It

Background: Rotator cuff tears are a common orthopaedic injury often resulting in shoulder pain and functional impairment. Despite the prevalence of rotator cuff tears, the incidence of retear after rotator cuff repair (RCR) remains high. There is growing interest in the use of structural augmentation in RCR to decrease retear rates and improve patient outcomes. Purpose: The purpose of this systematic review and meta-analysis was to compare the clinical and imaging outcomes of structural augmentation versus standard RCR in patients with full-thickness rotator cuff tears. The effectiveness of different augment subtypes was also assessed. Study Design: Meta-analysis; Level of evidence, 3. Methods: A comprehensive literature search was conducted in CENTRAL, Embase, and Medline from inception to November 13, 2024. Eligible studies included comparative trials evaluating structural augmentation in RCR for repairable full-thickness tears. Risk of bias was assessed using the Cochrane risk-of-bias tool for randomized controlled trials and the MINORS (Methodological Index for Non-randomized Studies) score for observational studies. Meta-analyses were performed via a random effects model, with subgroup analyses performed by study design and augment type. Results: Twenty-four studies (12 randomized controlled trials and 12 cohort studies) were included in this review, all of which evaluated biologic augments (xenograft, allograft, autograft). Structural augmentation significantly reduced the risk of retear by 35% as compared with standard RCR (risk ratio, 0.65; 95% CI, 0.48-0.89; P = .01). Retears were confirmed radiographically by magnetic resonance imaging or ultrasound. Subgroup analysis revealed the greatest reduction in retear rates with allograft augmentation (risk ratio, 0.34; 95% CI, 0.21-0.56). No significant differences were observed in patient-reported outcomes, including pain scores, American Shoulder and Elbow Surgeons scores, or Constant scores. Conclusion: Structural augmentation in RCR significantly reduces retear rates, particularly with allografts, but does not improve short-term patient-reported outcomes. Further research is needed to identify which patient and tear characteristics may influence the effectiveness of augmentation.
Research Code Sharing in Support of Gold Standard Science
Klonoff, David C., Espinoza, Juan, Mader, Julia K., Heinemann, Lutz, Cobelli, Claudio, Kerr, David , Kovatchev, Boris, Najafi, Bijan , Prahalad, Priya , Zheng, Yaguang , Shao, Mandy M. , Scheideman, Agatha F. , DuNova, Ashley Y. , Kohn, Michael , Umpierrez, Guillermo E., Malek, Aiman Abdel, Agus, Michael S. D., Ahn, David T., AlSaad, Rawan , AL-SOFIANI, MOHAMMED, Armstrong, David, Arnold, Mark A., Bequette, B. Wayne , Bellazzi, Riccardo, Cengiz, Eda, Chase, J. Geoffrey, Chen, Jake Y. , Cichosz, Simon Lebech , Clements, Mark A. , Close, Kelly L., Cuadros, Jorge , Contreras, Ivan, Drincic, Andjela , Facchinetti, Andrea, Fleming, G. Alexander , Gabbay, Monica A. L., Healey, Elizabeth, Hoang, Thanh D., Kulzer, Bernhard, Belle, Jeff La, Lee, Aaron, Lee, Cecilia S., Lee, Wei-An , Liepmann, Dorian , Maahs, David M. , Mathioudakis, Nestoras, Metwally, Ahmed A., Mohan, Viswanathan, Moon, Sun-Joon, Raeder, Helge, Rhee, Connie, Rhee, Eun-Jung, Scheinker, David , Shah, Viral N., Snyder, Michael P., Sode, Koji, Spanakis, Elias K., Svensson, Jannet, Vaswani, Nitin, Vareth, Maryam, Wallia, Amisha , Wang, Tao, Williams, Ebonie, Wolf, Ruth, Wong, Jenise C., Yeshiwas, Sewagegn, Shah, Shahid N. , Cobelli, Claudio , Snyder, M , Kovatchev, Boris , Heinemann, Lutz , Espinoza, Juan , Mathioudakis, Nestoras , Mader, Julia K. , Klonoff, David C , Espinoza, Juan , Mader, Julia K , Heinemann, Lutz , Cobelli, Claudio , Kovatchev, Boris , Umpierrez, Guillermo E. , Wong, Tien Y , Abdel Malek, Aiman , Agus, Michael S D , Ahn, David T , AlSaad, Rawan , Al-Sofiani, Mohammed E , Armstrong, David , Arnold, Mark A , Bee, Yong Mong , Bequette, B Wayne , Bellazzi, Riccardo , Cengiz, Eda , Chase, James Geoffrey , Chen, Haipeng , Chen, Jake Y , Cichosz, Simon L , Cinar, Ali , Clements, Mark A , Close, Kelly L , Cuadros, Jorge , Contreras, Ivan , Datta, Gora , Dhatariya, Ketan , Doyle, Francis J , Drincic, Angela , Facchinetti, Andrea , Fleming, G Alexander , Foreman, Joshua , Gabbay, Monica A L , Gutierrez-Osuna, Ricardo , Healey, Elizabeth , Hoang, Thanh D , Jacobs, Peter G , Kulzer, Bernhard , La Belle, Jeff , Lee, Aaron Y , Lee, Cecilia S , Lee, Wei-An Andy , Liepmann, Dorian , Maahs, David M , Mathioudakis, Nestoras N , Meo, Sultan A , Metwally, Ahmed A , Misra, Shivani , Mohan, Viswanathan , Moon, Sun-Joon , Raeder, Helge , Rhee, Connie M , Rhee, Eun-Jung , Scheinker, David , Shah, Viral N , Sheng, Bin , Snyder, Michael , Sode, Koji , Spanakis, Elias K , Svensson, Jannet , Vaswani, Nitin , Vareth, Maryam , Vehi, Josep , Wallia, Amisha , Waki, Kayo , Wang, Tao , Williams, Eric , Wolf, Risa M , Wong, Jenise C , Bekele, Sewagegn Yeshiwas , Zilbermint, Mihail , Shah, Shahid N , Klonoff, David C. , DuBord, Ashley Y., Wong, Tien Yin , Agus, Michael S. D. , Ahn, David , Close, Kelly L. , Dhatariya, Ketan , Doyle, Francis J. , Rhee, Connie M. , Sode, Koji , Spanakis, Elias K. , Waki, Kayo , Wong, Jenise C. , Zilbermint, Mihail

Mayo Clinic

Journal of Diabetes Science and Technology | January 14, 2026 | Volume: 20 | Issue: 3 | Pages: 609-619

10.1177/19322968251391819 | PMID 41532590 Get It

Sharing research code in an open access version-controlled repository offers significant benefits for both science as a whole and for individual researchers. In this article, we focus on this practice, which is fully aligned with the NIH’s Gold Standard Science (GSS) program as well as FAIR (findable, accessible, interoperable, reusable) and TRUST (transparency, responsibility, user focus, sustainability, technology) principles. Gold Standard Science supports open science by emphasizing transparency, reproducibility, and the use of best practices that enable others to verify and extend research. Pairing a research article’s cited data snapshot with a versioned, environment-specific code release, deposited in a companion code repository, ensures that, upon submission to a medical journal, readers and reviewers can directly verify results. An executable and updatable companion code repository complements, rather than replaces, established research data repositories. When code underlying medical research results is made openly available, then other scientists can inspect, run, and validate analyses. These activities enhance reproducibility, which is a core aim of GSS. Shared code also facilitates collaborative innovation by allowing researchers to extend the utility of the code to new datasets and applications. For researchers, code sharing can increase visibility, credibility, and citation impact. Demonstrating transparency through shared executable and updatable code builds trust with journal readers, peer reviewers, funders, and peers. Shared code in an open access repository signals adherence to high standards of scientific integrity and attracts opportunities for collaboration. A researcher who shares code receives recognition as a leader in reproducible, trustworthy research consistent with NIH’s GSS principles.